Annual EBIT
$4.84 B
+$562.80 M+13.17%
December 31, 2024
Summary
- As of February 25, 2025, REGN annual earnings before interest & taxes is $4.84 billion, with the most recent change of +$562.80 million (+13.17%) on December 31, 2024.
- During the last 3 years, REGN annual EBIT has fallen by -$4.55 billion (-48.47%).
- REGN annual EBIT is now -48.47% below its all-time high of $9.38 billion, reached on December 31, 2021.
Performance
REGN EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$968.60 M
-$538.20 M-35.72%
December 31, 2024
Summary
- As of February 25, 2025, REGN quarterly earnings before interest & taxes is $968.60 million, with the most recent change of -$538.20 million (-35.72%) on December 31, 2024.
- Over the past year, REGN quarterly EBIT has dropped by -$197.30 million (-16.92%).
- REGN quarterly EBIT is now -74.29% below its all-time high of $3.77 billion, reached on June 30, 2021.
Performance
REGN Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$4.84 B
-$197.30 M-3.92%
December 31, 2024
Summary
- As of February 25, 2025, REGN TTM earnings before interest & taxes is $4.84 billion, with the most recent change of -$197.30 million (-3.92%) on December 31, 2024.
- Over the past year, REGN TTM EBIT has increased by +$562.80 million (+13.17%).
- REGN TTM EBIT is now -48.47% below its all-time high of $9.38 billion, reached on December 31, 2021.
Performance
REGN TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
REGN EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.2% | -16.9% | +13.2% |
| 3 y3 years | -48.5% | -16.9% | +13.2% |
| 5 y5 years | +96.6% | -16.9% | +13.2% |
REGN EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -48.5% | +13.2% | -61.5% | +35.1% | -48.5% | +17.6% |
| 5 y | 5-year | -48.5% | +96.6% | -74.3% | +43.6% | -48.5% | +96.6% |
| alltime | all time | -48.5% | +2498.2% | -74.3% | +1732.8% | -48.5% | +2498.2% |
Regeneron Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $4.84 B(+13.2%) | $968.60 M(-35.7%) | $4.84 B(-3.9%) |
| Sep 2024 | - | $1.51 B(-8.3%) | $5.03 B(+8.1%) |
| Jun 2024 | - | $1.64 B(+129.2%) | $4.65 B(+13.2%) |
| Mar 2024 | - | $716.80 M(-38.5%) | $4.11 B(-3.7%) |
| Dec 2023 | $4.27 B(-13.1%) | $1.17 B(+3.3%) | $4.27 B(-4.0%) |
| Sep 2023 | - | $1.13 B(+2.4%) | $4.45 B(-8.2%) |
| Jun 2023 | - | $1.10 B(+25.8%) | $4.84 B(+2.7%) |
| Mar 2023 | - | $876.00 M(-34.7%) | $4.72 B(-4.0%) |
| Dec 2022 | $4.92 B(-47.6%) | $1.34 B(-12.0%) | $4.92 B(-19.3%) |
| Sep 2022 | - | $1.53 B(+56.2%) | $6.09 B(-4.8%) |
| Jun 2022 | - | $976.30 M(-9.2%) | $6.40 B(-30.4%) |
| Mar 2022 | - | $1.07 B(-57.3%) | $9.19 B(-2.1%) |
| Dec 2021 | $9.38 B(+142.6%) | $2.52 B(+37.5%) | $9.38 B(+15.8%) |
| Sep 2021 | - | $1.83 B(-51.4%) | $8.11 B(+11.0%) |
| Jun 2021 | - | $3.77 B(+197.2%) | $7.30 B(+63.6%) |
| Mar 2021 | - | $1.27 B(+2.3%) | $4.46 B(+15.3%) |
| Dec 2020 | $3.87 B(+57.3%) | $1.24 B(+21.0%) | $3.87 B(+9.7%) |
| Sep 2020 | - | $1.02 B(+10.3%) | $3.52 B(+7.6%) |
| Jun 2020 | - | $928.60 M(+37.6%) | $3.28 B(+27.0%) |
| Mar 2020 | - | $674.70 M(-24.7%) | $2.58 B(+4.9%) |
| Dec 2019 | $2.46 B(-4.7%) | $896.50 M(+15.5%) | $2.46 B(+9.5%) |
| Sep 2019 | - | $776.30 M(+233.6%) | $2.25 B(+6.3%) |
| Jun 2019 | - | $232.70 M(-58.0%) | $2.11 B(-16.9%) |
| Mar 2019 | - | $553.80 M(-19.0%) | $2.54 B(-1.5%) |
| Dec 2018 | $2.58 B(+22.7%) | $683.60 M(+6.3%) | $2.58 B(+5.0%) |
| Sep 2018 | - | $643.30 M(-3.0%) | $2.46 B(+3.0%) |
| Jun 2018 | - | $663.00 M(+12.0%) | $2.39 B(+5.8%) |
| Mar 2018 | - | $591.80 M(+5.5%) | $2.26 B(+7.2%) |
| Dec 2017 | $2.10 B(+57.3%) | $560.77 M(-1.9%) | $2.10 B(+11.5%) |
| Sep 2017 | - | $571.79 M(+7.6%) | $1.89 B(+12.2%) |
| Jun 2017 | - | $531.25 M(+20.8%) | $1.68 B(+16.5%) |
| Mar 2017 | - | $439.79 M(+27.7%) | $1.44 B(+8.0%) |
| Dec 2016 | $1.34 B(+7.9%) | $344.32 M(-6.0%) | $1.34 B(+10.8%) |
| Sep 2016 | - | $366.38 M(+24.8%) | $1.21 B(-2.3%) |
| Jun 2016 | - | $293.51 M(-11.8%) | $1.24 B(-4.1%) |
| Mar 2016 | - | $332.79 M(+55.1%) | $1.29 B(+4.0%) |
| Dec 2015 | $1.24 B(+55.2%) | $214.53 M(-45.6%) | $1.24 B(+1.5%) |
| Sep 2015 | - | $394.56 M(+13.9%) | $1.22 B(+20.0%) |
| Jun 2015 | - | $346.51 M(+22.1%) | $1.02 B(+14.3%) |
| Mar 2015 | - | $283.73 M(+44.7%) | $889.84 M(+11.4%) |
| Dec 2014 | $798.61 M(+7.5%) | $196.07 M(+2.6%) | $798.61 M(+0.4%) |
| Sep 2014 | - | $191.06 M(-12.8%) | $795.37 M(-5.5%) |
| Jun 2014 | - | $218.98 M(+13.8%) | $841.74 M(+7.7%) |
| Mar 2014 | - | $192.50 M(-0.2%) | $781.81 M(+5.2%) |
| Dec 2013 | $742.82 M(+61.6%) | $192.84 M(-18.8%) | $742.82 M(+6.7%) |
| Sep 2013 | - | $237.42 M(+49.3%) | $696.04 M(+5.2%) |
| Jun 2013 | - | $159.06 M(+3.6%) | $661.50 M(+12.0%) |
| Mar 2013 | - | $153.51 M(+5.1%) | $590.42 M(+28.4%) |
| Dec 2012 | $459.73 M(-328.0%) | $146.05 M(-28.0%) | $459.73 M(+70.9%) |
| Sep 2012 | - | $202.88 M(+130.6%) | $269.07 M(+3086.1%) |
| Jun 2012 | - | $87.98 M(+285.7%) | $8.45 M(-106.1%) |
| Mar 2012 | - | $22.81 M(-151.1%) | -$138.85 M(-31.1%) |
| Dec 2011 | -$201.61 M(+111.4%) | -$44.60 M(-22.8%) | -$201.61 M(+19.2%) |
| Sep 2011 | - | -$57.74 M(-2.7%) | -$169.15 M(+18.2%) |
| Jun 2011 | - | -$59.32 M(+48.5%) | -$143.04 M(+33.9%) |
| Mar 2011 | - | -$39.94 M(+229.1%) | -$106.86 M(+12.1%) |
| Dec 2010 | -$95.35 M(+37.0%) | -$12.14 M(-61.6%) | -$95.35 M(-19.3%) |
| Sep 2010 | - | -$31.64 M(+36.8%) | -$118.13 M(+34.6%) |
| Jun 2010 | - | -$23.13 M(-18.7%) | -$87.78 M(+8.5%) |
| Mar 2010 | - | -$28.44 M(-18.6%) | -$80.92 M(+19.2%) |
| Dec 2009 | -$69.61 M(+0.9%) | -$34.92 M(+2604.9%) | -$67.86 M(+45.2%) |
| Sep 2009 | - | -$1.29 M(-92.1%) | -$46.74 M(-28.5%) |
| Jun 2009 | - | -$16.27 M(+5.7%) | -$65.38 M(-4.9%) |
| Mar 2009 | - | -$15.39 M(+11.5%) | -$68.73 M(-0.8%) |
| Dec 2008 | -$69.03 M(-26.2%) | -$13.79 M(-30.8%) | -$69.26 M(+50.2%) |
| Sep 2008 | - | -$19.93 M(+1.6%) | -$46.10 M(-28.9%) |
| Jun 2008 | - | -$19.62 M(+23.3%) | -$64.83 M(-14.5%) |
| Mar 2008 | - | -$15.91 M(-269.9%) | -$75.82 M(-19.0%) |
| Dec 2007 | -$93.56 M | $9.36 M(-124.2%) | -$93.56 M(-31.4%) |
| Sep 2007 | - | -$38.67 M(+26.3%) | -$136.41 M(+8.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2007 | - | -$30.60 M(-9.0%) | -$126.00 M(+5.3%) |
| Mar 2007 | - | -$33.65 M(+0.5%) | -$119.64 M(+11.1%) |
| Dec 2006 | -$107.66 M(-186.5%) | -$33.49 M(+18.5%) | -$107.66 M(-174.2%) |
| Sep 2006 | - | -$28.26 M(+16.5%) | $145.15 M(+4.4%) |
| Jun 2006 | - | -$24.25 M(+11.9%) | $139.02 M(+6.0%) |
| Mar 2006 | - | -$21.66 M(-109.9%) | $131.10 M(+5.4%) |
| Dec 2005 | $124.42 M(+2103.7%) | $219.31 M(-737.8%) | $124.42 M(-236.8%) |
| Sep 2005 | - | -$34.39 M(+6.9%) | -$90.92 M(+37.7%) |
| Jun 2005 | - | -$32.17 M(+13.5%) | -$66.01 M(+42.0%) |
| Mar 2005 | - | -$28.34 M(-813.1%) | -$46.49 M(-923.4%) |
| Dec 2004 | $5.65 M(-105.6%) | $3.97 M(-141.9%) | $5.65 M(-136.5%) |
| Sep 2004 | - | -$9.48 M(-25.0%) | -$15.47 M(-51.2%) |
| Jun 2004 | - | -$12.64 M(-153.1%) | -$31.69 M(-33.4%) |
| Mar 2004 | - | $23.79 M(-238.8%) | -$47.60 M(-52.3%) |
| Dec 2003 | -$99.99 M(-18.0%) | -$17.14 M(-33.3%) | -$99.78 M(-14.9%) |
| Sep 2003 | - | -$25.70 M(-10.0%) | -$117.27 M(-5.2%) |
| Jun 2003 | - | -$28.56 M(+0.6%) | -$123.74 M(-1.1%) |
| Mar 2003 | - | -$28.38 M(-18.1%) | -$125.14 M(+2.6%) |
| Dec 2002 | -$121.95 M(+42.3%) | -$34.63 M(+7.6%) | -$121.95 M(+4.3%) |
| Sep 2002 | - | -$32.18 M(+7.4%) | -$116.91 M(+8.2%) |
| Jun 2002 | - | -$29.95 M(+18.9%) | -$108.03 M(+12.3%) |
| Mar 2002 | - | -$25.19 M(-14.9%) | -$96.17 M(+12.2%) |
| Dec 2001 | -$85.68 M(+239.0%) | -$29.59 M(+27.0%) | -$85.68 M(+30.1%) |
| Sep 2001 | - | -$23.29 M(+28.8%) | -$65.88 M(+13.4%) |
| Jun 2001 | - | -$18.09 M(+22.9%) | -$58.07 M(+32.4%) |
| Mar 2001 | - | -$14.71 M(+50.3%) | -$43.87 M(+16.6%) |
| Dec 2000 | -$25.28 M(+6.2%) | -$9.79 M(-36.8%) | -$37.64 M(+31.8%) |
| Sep 2000 | - | -$15.49 M(+298.9%) | -$28.55 M(+57.2%) |
| Jun 2000 | - | -$3.88 M(-54.2%) | -$18.16 M(-19.9%) |
| Mar 2000 | - | -$8.48 M(+1111.4%) | -$22.68 M(-7.8%) |
| Dec 1999 | -$23.80 M(+90.4%) | -$700.00 K(-86.3%) | -$24.60 M(-17.7%) |
| Sep 1999 | - | -$5.10 M(-39.3%) | -$29.90 M(+9.9%) |
| Jun 1999 | - | -$8.40 M(-19.2%) | -$27.20 M(+50.3%) |
| Mar 1999 | - | -$10.40 M(+73.3%) | -$18.10 M(+43.7%) |
| Dec 1998 | -$12.50 M(-8.8%) | -$6.00 M(+150.0%) | -$12.60 M(+8.6%) |
| Sep 1998 | - | -$2.40 M(-442.9%) | -$11.60 M(+12.6%) |
| Jun 1998 | - | $700.00 K(-114.3%) | -$10.30 M(-29.9%) |
| Mar 1998 | - | -$4.90 M(-2.0%) | -$14.70 M(+5.8%) |
| Dec 1997 | -$13.70 M(-20.8%) | -$5.00 M(+354.5%) | -$13.90 M(+3.7%) |
| Sep 1997 | - | -$1.10 M(-70.3%) | -$13.40 M(-19.8%) |
| Jun 1997 | - | -$3.70 M(-9.8%) | -$16.70 M(0.0%) |
| Mar 1997 | - | -$4.10 M(-8.9%) | -$16.70 M(-3.5%) |
| Dec 1996 | -$17.30 M(+127.6%) | -$4.50 M(+2.3%) | -$17.30 M(+11.6%) |
| Sep 1996 | - | -$4.40 M(+18.9%) | -$15.50 M(+14.8%) |
| Jun 1996 | - | -$3.70 M(-21.3%) | -$13.50 M(+21.6%) |
| Mar 1996 | - | -$4.70 M(+74.1%) | -$11.10 M(+30.6%) |
| Dec 1995 | -$7.60 M(-74.0%) | -$2.70 M(+12.5%) | -$8.50 M(-22.0%) |
| Sep 1995 | - | -$2.40 M(+84.6%) | -$10.90 M(-10.7%) |
| Jun 1995 | - | -$1.30 M(-38.1%) | -$12.20 M(-41.6%) |
| Mar 1995 | - | -$2.10 M(-58.8%) | -$20.90 M(-28.4%) |
| Dec 1994 | -$29.20 M(-24.7%) | -$5.10 M(+37.8%) | -$29.20 M(-17.3%) |
| Sep 1994 | - | -$3.70 M(-63.0%) | -$35.30 M(-13.7%) |
| Jun 1994 | - | -$10.00 M(-3.8%) | -$40.90 M(+0.5%) |
| Mar 1994 | - | -$10.40 M(-7.1%) | -$40.70 M(+3.0%) |
| Dec 1993 | -$38.80 M(+112.0%) | -$11.20 M(+20.4%) | -$39.50 M(+14.8%) |
| Sep 1993 | - | -$9.30 M(-5.1%) | -$34.40 M(+12.1%) |
| Jun 1993 | - | -$9.80 M(+6.5%) | -$30.70 M(+25.8%) |
| Mar 1993 | - | -$9.20 M(+50.8%) | -$24.40 M(+32.6%) |
| Dec 1992 | -$18.30 M(+90.6%) | -$6.10 M(+8.9%) | -$18.40 M(+15.0%) |
| Sep 1992 | - | -$5.60 M(+60.0%) | -$16.00 M(+24.0%) |
| Jun 1992 | - | -$3.50 M(+9.4%) | -$12.90 M(+13.2%) |
| Mar 1992 | - | -$3.20 M(-13.5%) | -$11.40 M(+83.9%) |
| Dec 1991 | -$9.60 M(+190.9%) | -$3.70 M(+48.0%) | -$6.20 M(-34.7%) |
| Sep 1991 | - | -$2.50 M(+25.0%) | -$9.50 M(+66.7%) |
| Jun 1991 | - | -$2.00 M(-200.0%) | -$5.70 M(+128.0%) |
| Mar 1991 | - | $2.00 M(-128.6%) | -$2.50 M(-24.2%) |
| Dec 1990 | -$3.30 M | -$7.00 M(-638.5%) | -$3.30 M(-189.2%) |
| Sep 1990 | - | $1.30 M(+8.3%) | $3.70 M(+54.2%) |
| Jun 1990 | - | $1.20 M(0.0%) | $2.40 M(+100.0%) |
| Mar 1990 | - | $1.20 M | $1.20 M |
FAQ
- What is Regeneron Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual EBIT year-on-year change?
- What is Regeneron Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly EBIT year-on-year change?
- What is Regeneron Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM EBIT year-on-year change?
What is Regeneron Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of REGN is $4.84 B
What is the all time high annual EBIT for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual earnings before interest & taxes is $9.38 B
What is Regeneron Pharmaceuticals annual EBIT year-on-year change?
Over the past year, REGN annual earnings before interest & taxes has changed by +$562.80 M (+13.17%)
What is Regeneron Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of REGN is $968.60 M
What is the all time high quarterly EBIT for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly earnings before interest & taxes is $3.77 B
What is Regeneron Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, REGN quarterly earnings before interest & taxes has changed by -$197.30 M (-16.92%)
What is Regeneron Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of REGN is $4.84 B
What is the all time high TTM EBIT for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM earnings before interest & taxes is $9.38 B
What is Regeneron Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, REGN TTM earnings before interest & taxes has changed by +$562.80 M (+13.17%)